Is AMGN a good stock to buy right now?

Based on our 6-factor quantitative model, AMGEN INC (AMGN) receives a "Hold" rating with a composite score of 49.4/100. It is ranked #713 out of 4,446 stocks. Key factor scores: Quality 50/100, Value 56/100, Momentum 56/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for AMGN?

AMGEN INC (AMGN) has a "Hold" rating and 3-star score. The composite score of 49.4 ranks it #713 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is AMGN in?

AMGEN INC operates in the Healthcare sector (Pharmaceutical Products industry) with a market cap of $190.44 billion. It is classified as a large-cap stock.

Does AMGN pay a dividend?

Yes, AMGN pays a dividend with a current yield of 3.33%. For every $1,000 invested, you would receive approximately $33.30 in annual dividend income.

What is AMGN's P/E ratio?

AMGN has a trailing P/E ratio of 19.90x. The Healthcare sector average is 23.6x. This P/E is in a moderate range relative to the broader market.

How profitable is AMGN?

AMGN's quality factor score is 50/100. Gross margin: 64.9%. ROE: 106.3% vs sector average -43.5%. High margins suggest pricing power and competitive moats.

How is AMGN valued compared to peers?

AMGN's value factor score is 56/100 (higher = cheaper). Key multiples: P/E 19.9x, EV/EBITDA 26.2x. Valuation is roughly in line with peers.

What is AMGN's debt level?

AMGN's debt-to-equity ratio is 631%. Sector average: 32%. Elevated leverage increases credit risk.

AMGN has a beta of 0.44, meaning it is less volatile than the market. Stability score: 84/100.

Does AMGN have high short interest?

AMGN's short interest factor score is 8/100 (higher = less short selling). Elevated short interest may indicate bearish sentiment or short squeeze potential.

AMGN Stock Analysis: Hold (Score 49.4/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
AMGN	-1.29%	+0.89%	-6.50%	+7.24%	+24.74%	-	-	-
Industry Proxy XLV	-1.35%	+0.34%	-3.81%	-4.84%	+9.21%	-	-	-
U.S. Market SPY	-0.07%	+3.60%	+0.34%	-0.36%	+29.52%	-	-	-
Alpha vs Market	-1.22%	-2.72%	-6.84%	+7.60%	-4.79%	-	-	-
Alpha vs Sector	+0.06%	+0.54%	-2.69%	+12.08%	+15.53%	-	-	-

Metric	AMGN	Benchmark
P/E Ratio	19.9x	-16%
EV/EBITDA	26.2x	+314%
Price / Book	21.2x

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
AZN ASTRAZENECA PLC	61	43	77	87	45.2x	88.7%	68.6%	28.3%	-	37.0x	$311.3B	VS
SLGL Sol-Gel Technologies Ltd.	57	41	36	98	-	-146.7%	100.0%	-91.7%	-	0.0x	$271M	VS
VMD VIEMED HEALTHCARE, INC.	53	50	63	60	27.6x	9.4%	57.8%	5.4%	30.8%	39.0x	$370M	VS
INVA Innoviva, Inc.	53	50	72	60	15.9x	9.2%	78.6%	23.9%	7.9%	39.0x	$1.7B	VS
HOLX HOLOGIC INC	53	50	43	58	31.7x	10.2%	51.4%	12.9%	3.6%	48.0x	$16.9B	VS
FONR FONAR CORP	52	48	50	57	11.1x	6.5%	88.3%	10.1%	2.4%	33.0x	$117M	VS
JNJ JOHNSON & JOHNSON	52	50	39	65	21.4x	32.9%	67.8%	29.0%	9.3%	51.0x	$588.0B	VS
UTHR UNITED THERAPEUTICS Corp	51	50	63	66	19.4x	18.0%	88.4%	40.7%	11.8%	11.0x	$25.0B	VS
DGX QUEST DIAGNOSTICS INC	51	50	62	55	21.2x	14.2%	33.2%	9.6%	17.5%	79.0x	$21.7B	VS
AMGN AMGEN INC	49	50	56	56	19.9x	106.4%	64.9%	25.9%	13.9%	631.0x	$190.4B
PFE PFIZER INC	49	50	59	48	11.1x	16.1%	74.7%	22.1%	25.4%	140.0x	$162.4B	VS

Key Ratio	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Gross Margin %	0.6%	0.7%	0.6%	0.7%	0.8%	0.8%	0.8%	0.8%	0.8%	0.8%	0.8%
Operating Margin %	0.2%	0.2%	0.2%	0.3%	0.4%	0.3%	0.4%	0.4%	0.4%	0.4%	0.4%
EBITDA Margin %	0.3%	0.3%	0.4%	0.3%	0.4%	0.3%	0.5%	0.5%	0.5%	0.6%	0.5%
Net Margin %	0.3%	0.2%	0.1%	0.2%	0.2%	0.2%	0.3%	0.3%	0.4%	0.1%	0.3%
FCF Margin %	17.6%	-	31.1%	-	-	-	38.9%	36.5%	44.5%	46.0%	41.8%
ROE %	1.1%	0.9%	0.7%	1.1%	1.8%	0.9%	0.8%	0.8%	0.7%	0.1%	0.3%
ROA %	0.1%	0.1%	0.0%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.0%	0.1%
ROIC %	0.1%	11.3%	10.6%	8.8%	17.7%	15.1%	20.0%	22.8%	20.5%	13.9%	12.6%

Key Ratio

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

Gross Margin %

0.6%

0.7%

0.6%

0.7%

0.8%

Operating Margin %

0.2%

0.3%

0.4%

0.3%

0.4%

EBITDA Margin %

0.3%

0.4%

0.3%

0.4%

0.3%

0.5%

0.6%

0.5%

Net Margin %

0.3%

0.2%

0.1%

0.2%

0.3%

0.4%

0.1%

0.3%

FCF Margin %

17.6%

31.1%

38.9%

36.5%

44.5%

46.0%

41.8%

ROE %

1.1%

0.9%

0.7%

1.1%

1.8%

0.9%

0.8%

0.7%

0.1%

0.3%

ROA %

0.1%

0.0%

0.1%

0.0%

0.1%

ROIC %

0.1%

11.3%

10.6%

8.8%

17.7%

15.1%

20.0%

22.8%

20.5%

13.9%

12.6%

Line Item	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
	$35.4B	$36.8B	$33.4B	$28.2B	$26.3B	$26.0B	$25.4B	$23.4B	$23.7B	$22.8B	$23.0B	$21.7B
	—	$12.0B	—	$8.5B	$6.4B	$6.5B	—	—	—	—	—	—
	$23.0B	$24.7B	$20.6B	$19.7B	$19.9B	$19.5B	$19.3B	$19.0B	$19.6B	$18.8B	$18.8B	$17.4B
Gross Margin	64.9%	67.3%	61.5%	70.0%	75.7%	75.2%	75.8%	81.3%	82.7%	82.2%	81.9%	80.5%
	—	$7.0B	—	$6.2B	$5.4B	$5.4B	—	—	—	—	—	—
Research & Development	—	—	$6.0B	—	—	—	$4.2B	$4.1B	$3.7B	$3.6B	$3.8B	$4.1B
Depreciation	—	$887M	$5.6B	—	—	—	$3.6B	$2.2B	$1.9B	$2.0B	$2.1B	$2.1B
Total Operating Expenses	—	$15.6B	—	$11.8B	$10.4B	$11.9B	—	—	—	—	—	—
	$8.4B	$9.1B	$7.3B	$7.9B	$9.6B	$7.6B	$9.1B	$9.7B	$10.3B	$10.0B	$9.8B	$8.5B
EBIT	$8.4B	$9.1B	$7.3B	$7.9B	$9.6B	$7.6B	$9.1B	$9.7B	$10.3B	$10.0B	$9.8B	$8.5B
EBITDA	$9.1B	$10.0B	$13.4B	$7.9B	$9.6B	$7.6B	$13.0B	$12.6B	$12.9B	$12.9B	$12.5B	$11.2B
Operating Margin	23.5%	24.7%	21.7%	28.0%	36.3%	29.4%	35.9%	41.4%	43.2%	43.6%	42.6%	39.1%
EBITDA Margin	25.6%	27.1%	40.0%	28.0%	36.3%	29.4%	51.1%	54.1%	54.3%	56.3%	54.5%	51.6%
	—	—	$3.2B	—	—	—	$1.3B	$1.3B	$1.4B	$1.3B	$1.3B	$1.1B
	—	$9.0B	—	$7.9B	$7.3B	$6.7B	—	—	—	—	—	—
Income Tax Expense	—	$1.3B	$519M	$1.1B	$794M	$808M	$869M	$1.3B	$1.2B	$7.6B	$1.4B	$1.0B
	$9.2B	$7.7B	$4.1B	$6.7B	$6.6B	$5.9B	$7.3B	$7.8B	$8.4B	$2.0B	$7.7B	$6.9B
Net Margin	25.9%	21.0%	12.2%	23.8%	24.9%	22.7%	28.6%	33.6%	35.4%	8.7%	33.6%	32.0%
	$14.33	$14.33	$7.62	$12.56	$12.18	$10.34	$12.40	$12.96	$12.70	$2.71	$10.32	$9.15
Diluted EPS	$14.33	$14.23	$7.62	$12.49	$12.11	$10.28	$12.40	$12.96	$12.70	$2.71	$10.32	$9.15
Weighted Avg Basic	—	538M	—	535M	538M	570M	—	—	—	—	—	—
Weighted Avg Diluted	—	542M	—	538M	541M	573M	—	—	—	—	—	—

Line Item

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

$35.4B

$36.8B

$33.4B

$28.2B

$26.3B

$26.0B

$25.4B

$23.4B

$23.7B

$22.8B

$23.0B

$21.7B

—

$12.0B

—

$8.5B

$6.4B

$6.5B

—

$23.0B

$24.7B

$20.6B

$19.7B

$19.9B

$19.5B

$19.3B

$19.0B

$19.6B

$18.8B

$17.4B

Gross Margin

64.9%

67.3%

61.5%

70.0%

75.7%

75.2%

75.8%

81.3%

82.7%

82.2%

81.9%

80.5%

—

$7.0B

—

$6.2B

$5.4B

—

Research & Development

—

$6.0B

—

$4.2B

$4.1B

$3.7B

$3.6B

$3.8B

$4.1B

Depreciation

—

$887M

$5.6B

—

$3.6B

$2.2B

$1.9B

$2.0B

$2.1B

Total Operating Expenses

—

$15.6B

—

$11.8B

$10.4B

$11.9B

—

$8.4B

$9.1B

$7.3B

$7.9B

$9.6B

$7.6B

$9.1B

$9.7B

$10.3B

$10.0B

$9.8B

$8.5B

EBIT

$8.4B

$9.1B

$7.3B

$7.9B

$9.6B

$7.6B

$9.1B

$9.7B

$10.3B

$10.0B

$9.8B

$8.5B

EBITDA

$9.1B

$10.0B

$13.4B

$7.9B

$9.6B

$7.6B

$13.0B

$12.6B

$12.9B

$12.5B

$11.2B

Operating Margin

23.5%

24.7%

21.7%

28.0%

36.3%

29.4%

35.9%

41.4%

43.2%

43.6%

42.6%

39.1%

EBITDA Margin

25.6%

27.1%

40.0%

28.0%

36.3%

29.4%

51.1%

54.1%

54.3%

56.3%

54.5%

51.6%

—

$3.2B

—

$1.3B

$1.4B

$1.3B

$1.1B

—

$9.0B

—

$7.9B

$7.3B

$6.7B

—

Income Tax Expense

—

$1.3B

$519M

$1.1B

$794M

$808M

$869M

$1.3B

$1.2B

$7.6B

$1.4B

$1.0B

$9.2B

$7.7B

$4.1B

$6.7B

$6.6B

$5.9B

$7.3B

$7.8B

$8.4B

$2.0B

$7.7B

$6.9B

Net Margin

25.9%

21.0%

12.2%

23.8%

24.9%

22.7%

28.6%

33.6%

35.4%

8.7%

33.6%

32.0%

$14.33

$7.62

$12.56

$12.18

$10.34

$12.40

$12.96

$12.70

$2.71

$10.32

$9.15

Diluted EPS

$14.33

$14.23

$7.62

$12.49

$12.11

$10.28

$12.40

$12.96

$12.70

$2.71

$10.32

$9.15

Weighted Avg Basic

—

538M

—

535M

538M

570M

—

Weighted Avg Diluted

—

542M

—

538M

541M

573M

—

AMGEN INC (AMGN) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does AMGEN INC Do?

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California. AMGEN INC (AMGN) is classified as a large-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Robert A. Bradway and employs approximately 25,200 people, headquartered in Wilmington, California. With a market capitalization of $190.4B, AMGN is one of the prominent companies in the Healthcare sector.

AMGEN INC (AMGN) Stock Rating — Hold (April 2026)

As of April 2026, AMGEN INC receives a Hold rating with a composite score of 49.4/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.AMGN ranks #713 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, AMGEN INC ranks #47 of 838 stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

AMGN Stock Price and 52-Week Range

AMGEN INC (AMGN) currently trades at $352.00. The stock lost $3.60 (1.0%) in the most recent trading session. The 52-week high for AMGN is $390.14, which means the stock is currently trading -9.8% from its annual peak. The 52-week low is $261.43, putting the stock 34.6% above its annual trough. Recent trading volume was 2.3M shares, reflecting moderate market activity.

Is AMGN Overvalued or Undervalued? — Valuation Analysis

AMGEN INC (AMGN) carries a value factor score of 56/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 19.90x, compared to the Healthcare sector average of 23.63x — a discount of 16%. The price-to-book ratio stands at 21.17x, versus the sector average of 2.75x. The price-to-sales ratio is 5.18x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, AMGN trades at 26.23x EV/EBITDA, versus 6.34x for the sector.

Overall, AMGN's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

AMGEN INC Profitability — ROE, Margins, and Quality Score

AMGEN INC (AMGN) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 106.3%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at 10.2% versus the sector average of -33.1%.

On a margin basis, AMGEN INC reports gross margins of 64.9%, compared to 71.5% for the sector. The operating margin is 23.5% (sector: -66.1%). Net profit margin stands at 25.9%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 13.9% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.

AMGN Debt, Balance Sheet, and Financial Health

AMGEN INC has a debt-to-equity ratio of 631.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.14x, suggesting adequate working capital coverage. Total debt on the balance sheet is $54.60B. Cash and equivalents stand at $9.45B.

AMGN has a beta of 0.44, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for AMGEN INC is 84/100, indicating low-volatility characteristics and consistent price behavior that appeals to risk-averse investors.

AMGEN INC Revenue and Earnings History — Quarterly Trend

In TTM 2026, AMGEN INC reported revenue of $35.39B and earnings per share (EPS) of $14.33. Net income for the quarter was $9.21B. Gross margin was 64.9%. Operating income came in at $8.41B.

In FY 2025, AMGEN INC reported revenue of $36.75B and earnings per share (EPS) of $14.33. Net income for the quarter was $7.71B. Gross margin was 67.3%. Revenue grew 10.0% year-over-year compared to FY 2024. Operating income came in at $9.08B.

In Q3 2025, AMGEN INC reported revenue of $9.56B and earnings per share (EPS) of $5.98. Net income for the quarter was $3.22B. Gross margin was 67.8%. Revenue grew 12.4% year-over-year compared to Q3 2024. Operating income came in at $2.53B.

In Q2 2025, AMGEN INC reported revenue of $9.18B and earnings per share (EPS) of $2.66. Net income for the quarter was $1.43B. Gross margin was 67.2%. Revenue grew 9.4% year-over-year compared to Q2 2024. Operating income came in at $2.66B.

Over the past 8 quarters, AMGEN INC has demonstrated a growth trajectory, with revenue expanding from $8.39B to $35.39B. Investors analyzing AMGN stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

AMGN Dividend Yield and Income Analysis

AMGEN INC (AMGN) currently pays a dividend yield of 3.3%. At this yield, a $10,000 investment in AMGN stock would generate approximately $$333.00 in annual dividend income. With a net margin of 25.9%, the dividend appears well-covered by earnings, suggesting sustainable payouts going forward.

AMGN Momentum and Technical Analysis Profile

AMGEN INC (AMGN) has a momentum factor score of 56/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 28/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 8/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

AMGN vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, AMGEN INC (AMGN) ranks #47 out of 838 stocks based on the Blank Capital composite score. This places AMGN in the top decile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing AMGN against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full AMGN vs S&P 500 (SPY) comparison to assess how AMGEN INC stacks up against the broader market across all factor dimensions.

AMGN Next Earnings Date

No upcoming earnings date has been announced for AMGEN INC (AMGN) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy AMGN? — Investment Thesis Summary

AMGEN INC presents a balanced picture with arguments on both sides. Low volatility (stability score 84/100) reduces downside risk.

In summary, AMGEN INC (AMGN) earns a Hold rating with a composite score of 49.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on AMGN stock.

Related Resources for AMGN Investors

Explore more research and tools: AMGN vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare AMGN head-to-head with peers: AMGN vs AZN, AMGN vs SLGL, AMGN vs VMD.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

Is Amgen (AMGN) One of the Most Profitable Value Stocks to Buy Right Now?

Viridian Therapeutics price target lowered to $36 from $40 at Truist

Guggenheim Maintains Neutral on Amgen, Raises Price Target to $351

Amgen's lung cancer drug tarlatamabwins China approval

Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Related Healthcare Stocks

AMGEN INC (AMGN) Stock Analysis — April 2026 Rating, Price, and Forecast

Company Overview — What Does AMGEN INC Do?

AMGEN INC (AMGN) Stock Rating — Hold (April 2026)

AMGN Stock Price and 52-Week Range

Is AMGN Overvalued or Undervalued? — Valuation Analysis

AMGEN INC Profitability — ROE, Margins, and Quality Score

AMGN Debt, Balance Sheet, and Financial Health

AMGEN INC Revenue and Earnings History — Quarterly Trend

AMGN Dividend Yield and Income Analysis

AMGN Momentum and Technical Analysis Profile

AMGN vs Competitors — Healthcare Sector Ranking and Peer Comparison

AMGN Next Earnings Date

Should You Buy AMGN? — Investment Thesis Summary

Related Resources for AMGN Investors

Comments

Institutional Benchmarks

Related research

Get alerted on rating changes

Intelligence Feed

Is Amgen (AMGN) One of the Most Profitable Value Stocks to Buy Right Now?

Viridian Therapeutics price target lowered to $36 from $40 at Truist

Guggenheim Maintains Neutral on Amgen, Raises Price Target to $351

Amgen's lung cancer drug tarlatamabwins China approval

Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider